Diagnostic and Clinical Assessment of Psoriasis

1. Key Diagnostic Criteria

A personal or family history of psoriasis markedly increases diagnostic confidence, especially in atypical presentations. 1
The presence of well‑demarcated, indurated plaques with silvery‑white scales on the trunk is highly suggestive of psoriasis compared with other dermatoses. 1
Nail changes (pitting, onycholysis, subungual hyperkeratosis, “oil‑drop” sign) occur in roughly 50 % of all psoriasis patients and up to 90 % of those with psoriatic arthritis. 2

Subtype	Typical Features	Approximate Frequency
Plaque (Vulgar) Psoriasis	Erythematous, well‑bordered plaques with silvery scales on extensor surfaces.	Most common form.
Guttate Psoriasis	Small (1–10 mm) pink‑salmon papules with fine scale, often on trunk and proximal limbs; usually in patients < 30 years.	< 2 % of psoriasis cases.
Inverse Psoriasis	Red, smooth plaques with minimal scaling in intertriginous areas (axillae, genital, perineal, inframammary).	—
Erythrodermic Psoriasis	Generalized erythema covering most of the body with variable desquamation; may present with thermoregulatory disturbance, chills, fever, dehydration. Medical emergency.	—
Pustular Psoriasis	Visible neutrophil collections in the stratum corneum; can be generalized (von Zumbusch) with fever and diffuse pustules, or localized to palms/soles.	—

All subtype descriptions are based on expert consensus from the American Academy of Dermatology. 2

Atopic dermatitis, contact dermatitis, seborrheic dermatitis, and cutaneous T‑cell lymphoma can mimic erythrodermic psoriasis; a detailed personal/family history and the presence of indurated, silvery‑scaled plaques favor psoriasis. [1][5]
In suspected cutaneous T‑cell lymphoma, atypical lymphocytes on skin biopsy and peripheral blood flow cytometry (Sézary cells, T‑cell receptor gene rearrangement) are decisive. 1

Patient‑reported disability (“need for treatment”) and objective disease burden (extent and severity) should both be evaluated when grading psoriasis severity. 7
Psoriasis Area and Severity Index (PASI): Scores range 0–72, integrating affected body surface area, erythema, scaling, and plaque thickness. It is the most widely used objective outcome in clinical trials. 4
Body Surface Area (BSA): Simple percentage of skin involvement; however, disease can be severe despite low BSA if it causes significant emotional distress, involves critical sites, or produces intractable pruritus. 4
Quality‑of‑Life Measures (e.g., Dermatology Life Quality Index) are essential because psoriasis lesions can be disfiguring, painful, and intensely pruritic, profoundly affecting patients’ daily functioning. [2][8]

Psoriatic arthritis occurs in 6–40 % of psoriasis patients, with higher prevalence in severe skin disease; nail involvement is a key clinical clue. 6
Metabolic syndrome components (type 2 diabetes, obesity) are frequently observed in this population. [2][8]
Cardiovascular disease risk warrants age‑appropriate screening per American Cancer Society recommendations. 6
Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) shows increased prevalence among psoriasis patients. [2][8]
Cutaneous T‑cell lymphoma surveillance is advised when atypical lesions appear in the groin or buttocks, prompting lymph node examination and skin biopsy. 6

Stress, systemic infections, and certain medications (e.g., lithium, antimalarials, β‑blockers, NSAIDs, alcohol) can precipitate severe psoriasis flares. [5][4]
Patients requiring systemic or biologic agents should be managed under continuous dermatology specialist supervision because of potential drug toxicity. 7
Immediate specialist referral is indicated for erythrodermic or generalized pustular psoriasis (medical emergencies) and for any suspicion of cutaneous T‑cell lymphoma. [4][6]